CMMBNasdaqPharmaceutical PreparationsFiscal year ends December 31

Chemomab Therapeutics Ltd.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 23, 2026

$1.17−0.09 (-7.51%)

Close on Oct 19, 2026

Market cap: $749.09M
P/E (TTM): 65.0
Dividend yield: –

Chemomab Therapeutics Ltd. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	Q2 2026 2026-06-30	Q1 2026 2026-03-31	Q4 2025 2025-12-31	Q2 2025 2025-06-30	Q1 2025 2025-03-31	Q4 2024 2024-12-31	Q2 2024 2024-06-30	Q1 2024 2024-03-31	Q4 2023 2023-12-31	Q2 2023 2023-06-30	Q1 2023 2023-03-31	Q4 2022 2022-12-31	Q3 2022 2022-09-30	Q2 2022 2022-06-30	Q1 2022 2022-03-31	Q4 2021 2021-12-31	Q3 2021 2021-09-30	Q2 2021 2021-06-30	Q1 2021 2021-03-31	Q4 2020 2020-12-31	Q3 2020 2020-09-30	Q2 2020 2020-06-30	Q1 2020 2020-03-31	Q4 2019 2019-12-31	Q3 2019 2019-09-30	Q2 2019 2019-06-30	Q1 2019 2019-03-31	Q4 2018 2018-12-31	Q4 2017 2017-12-31	Q4 2016 2016-12-31	Q4 2015 2015-12-31
Cash & Equivalents	6.00	–	7.56	5.60	–	6.15	5.11	–	9.37	10	21	14	11	9.96	14	15	38	45	58	12	13	13	11	12	23	27	32	7.64	1.45	4.56	2.20
Cash & Short-Term Investments	6.70	–	10	9.50	–	14	5.11	–	9.37	10	21	14	11	9.96	14	15	38	45	58	12	13	13	11	12	23	27	32	7.64	1.45	4.56	2.20
Receivables	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.41	–	–	–	3.40	0.40	–	–
Prepaid Expenses & Other	3.27	–	3.06	1.10	–	1.70	0.65	–	1.04	1.04	1.00	1.77	2.26	3.11	1.93	1.53	1.57	1.92	0.32	0.14	0.62	0.85	0.54	0.64	–	–	–	–	–	–	–
Total Current Assets	9.96	–	13	11	–	16	13	–	21	28	34	42	49	55	59	63	66	69	60	12	7.39	9.67	15	18	–	–	–	11	1.85	–	–
Property, Plant & Equipment	0.16	–	0.18	0.22	–	0.25	0.28	–	0.30	0.34	0.35	0.37	0.38	0.36	0.36	0.36	0.23	0.24	0.15	0.15	0.02	0.02	0.12	0.16	–	–	–	0.39	0.22	–	–
Gross Property, Plant & Equipment	–	–	0.49	–	–	0.53	–	–	0.53	–	–	0.53	–	–	–	0.46	–	–	–	0.23	–	–	–	–	–	–	–	–	–	–	–
Accumulated Depreciation	–	–	-0.31	–	–	-0.28	–	–	-0.23	–	–	-0.17	–	–	–	-0.11	–	–	–	-0.07	–	–	–	–	–	–	–	–	–	–	–
Operating Lease Right-of-Use Assets	–	–	0	0	–	0.29	0.34	–	0.39	0.16	0.19	0.23	0.26	0.30	0.31	0.35	0.36	0.39	0.40	0.43	0.23	0.28	0.34	1.20	–	–	–	1.81	–	–	–
Other Long-Term Assets	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.05	0.05	0.05	0.05	0.06	–	–	–	–	–	–	–
Total Assets	10	–	14	11	–	17	15	–	22	29	35	43	50	56	61	64	67	71	60	12	7.69	10	15	20	–	–	–	13	2.09	–	–
Accrued Expenses	0.49	–	0.34	0.67	–	1.54	2.55	–	3.42	2.50	3.16	3.38	2.58	1.71	1.25	0.56	0.64	0.98	1.96	0.72	1.36	0.35	0.94	0.37	–	–	–	1.62	–	–	–
Current Portion of Leases	–	–	0	0	–	0.12	0.11	–	0.08	0.11	0.12	0.12	0.13	0.13	0.12	0.11	0.06	0.07	0.07	0.07	0.17	0.17	0.19	0.39	–	–	–	1.73	–	–	–
Other Current Liabilities	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1.73	1.62	0.61	2.68	2.86	–	–	–	1.71	–	–	–
Total Current Liabilities	1.55	–	1.48	1.43	–	3.22	4.31	–	4.84	6.83	7.00	6.75	5.48	4.39	3.52	2.65	1.63	2.16	4.63	1.32	2.28	1.75	3.47	4.12	–	–	–	2.75	2.70	–	–
Long-Term Leases	–	–	0	0	–	0.21	0.25	–	0.32	0.03	0.06	0.09	0.12	0.15	0.20	0.24	0.30	0.32	0.33	0.36	0.06	0.11	0.15	0.73	–	–	–	–	–	–	–
Operating Lease Liabilities	–	–	0	0	–	0.32	0.36	–	0.39	0.14	0.18	0.21	0.24	0.28	0.32	0.34	0.36	0.39	0.40	0.20	0.24	0.28	0.34	1.12	–	–	–	1.70	–	–	–
Total Liabilities	1.55	–	1.48	1.43	–	3.43	4.56	–	5.15	6.86	7.06	6.84	5.60	4.54	3.72	2.89	1.93	2.48	4.96	1.67	2.34	1.86	3.62	4.85	–	–	–	2.96	2.70	–	–
Common Stock	0	–	0	0	–	0	0	–	0	0	0	0	0	0	0	0	–	–	0	0	0	–	–	0	–	–	–	–	–	–	–
Additional Paid-In Capital	124	–	124	118	–	116	106	–	106	104	102	101	100	99	99	98	97	96	81	34	119	120	120	119	–	–	–	87	–	–	–
Retained Earnings	-116	–	-112	-108	–	-103	-96	–	-89	-81	-73	-64	-56	-47	-41	-36	-31	-28	-25	-24	-115	-112	-109	-105	–	–	–	-78	-63	–	–
Treasury Stock	–	–	–	–	–	–	–	–	0	-1.22	-1.22	-1.22	–	–	–	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Shareholders' Equity	8.69	11	12	9.70	10	14	9.99	13	17	22	28	36	45	52	57	61	66	68	55	11	12	13	11	12	20	27	31	9.81	-0.61	–	–
Total Equity	8.69	11	12	9.70	10	14	9.99	13	17	22	28	36	45	52	57	61	66	68	55	11	12	13	11	12	20	27	31	9.81	-0.61	3.30	2.14
Total Liabilities & Equity	10	–	14	11	–	17	15	–	22	29	35	43	50	56	61	64	67	71	60	12	7.69	10	15	20	–	–	–	13	2.09	–	–
Shares Outstanding(shares)	580	–	575	414	–	377	287	–	284	248	233	233	229	229	228	228	228	228	214	9.27	130	130	130	130	–	–	–	55	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -69.5%

Financial strength

Current ratio: 6.41
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 386.3%

Valuation

P/E ratio: 65.0
Price to sales: –
Price to book: 86.25
Dividend yield: –